H5O0 Stock Overview
A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.63 |
| 52 Week Low | AU$0.11 |
| Beta | 1.05 |
| 11 Month Change | 30.26% |
| 3 Month Change | 39.44% |
| 1 Year Change | -50.50% |
| 33 Year Change | -99.27% |
| 5 Year Change | n/a |
| Change since IPO | -99.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| H5O0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 13.1% | 3.1% | 4.5% |
| 1Y | -50.5% | -12.1% | 13.4% |
Return vs Industry: H5O0 underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: H5O0 underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| H5O0 volatility | |
|---|---|
| H5O0 Average Weekly Movement | 29.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H5O0's share price has been volatile over the past 3 months.
Volatility Over Time: H5O0's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | argentbiopharma.com |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
| H5O0 fundamental statistics | |
|---|---|
| Market cap | €10.63m |
| Earnings (TTM) | -€10.84m |
| Revenue (TTM) | €551.10k |
19.3x
P/S Ratio-1.0x
P/E RatioIs H5O0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H5O0 income statement (TTM) | |
|---|---|
| Revenue | AU$891.08k |
| Cost of Revenue | AU$1.20m |
| Gross Profit | -AU$304.15k |
| Other Expenses | AU$17.23m |
| Earnings | -AU$17.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | -34.13% |
| Net Profit Margin | -1,967.34% |
| Debt/Equity Ratio | -149.0% |
How did H5O0 perform over the long term?
See historical performance and comparison